District Of Columbia is currently home to 920 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Pompe Disease Registry Protocol
NCT00231400
Recruiting
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes. The objectives of the Registry are: To enhance understanding of the... Read More
Gender:
All
Ages:
All
Trial Updated:
01/31/2024
Locations: Children's National Medical Center Site Number : 840067, Washington, District of Columbia
Conditions: Glycogen Storage Disease Type II, Pompe Disease
Register for Updates
POC Study to Evaluate BSI-045B Monotherapy and BSI-045B add-on Therapy With Dupilumab in Atopic Dermatitis
NCT05932654
Recruiting
The study is a multicenter clinical trial and is designed as a proof-of-concept study to evaluate the efficacy, safety, tolerability, PK, immunogenicity, and PD of BSI-045B following SC injections, as monotherapy or as add-on therapy with dupilumab. The study will enroll patients with moderate to severe AD in 4 cohorts. There will be 2 Monotherapy Cohorts, assigned to different doses of BSI-045B: a 300 mg Cohort and a 480 mg Cohort. There will be 2 Add-on Therapy Cohorts, assigned to different... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
01/30/2024
Locations: The George Washington University School of Medicine and Health Science, Washington, District of Columbia
Conditions: Atopic Dermatitis
Register for Updates
A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
NCT03611868
Recruiting
Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab. Part 2 is phase II design of APG-115 at recommended phase 2 dose (RP2D) in combination with pembrolizumab.
Gender:
All
Ages:
12 years and above
Trial Updated:
01/30/2024
Locations: Children's National Research Institute, Washington, District of Columbia
Conditions: Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, MPNST, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors
Register for Updates
An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics
NCT05040178
Recruiting
To obtain short-term and long-term clinical safety information, in pediatric and adult patients with PA and MMA treated with Carbaglu®.
Gender:
All
Ages:
All
Trial Updated:
01/29/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Hyperammonemia, Methylmalonic Acidemia, Propionic Acidemia
Register for Updates
Efficacy Trial of Life Simulation Game to Routinize Adolescent HIV Testing
NCT04917575
Recruiting
This study will aim to assess the acceptability, usability and efficacy of using state-of-the-art video game technology to increase HIV testing among adolescents and young adults (AYA) ages 13-24. AYA often lack awareness of their personal risk of contracting HIV and where to go for testing and care. This lack of awareness has contributed to poor uptake of HIV testing among AYA despite engagement in high risk behaviors. The goal of this project is to harness this strong motivation to play games... Read More
Gender:
All
Ages:
Between 13 years and 24 years
Trial Updated:
01/29/2024
Locations: George Washington University Milken School of Public Health, Washington, District of Columbia
Conditions: Hiv
Register for Updates
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
NCT03827694
Recruiting
This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI).
Gender:
All
Ages:
Between 120 days and 21 years
Trial Updated:
01/29/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Pulmonary Invasive Aspergillosis, Pulmonary Invasive Fungal Infections
Register for Updates
Fecal Microbiota Transplant National Registry
NCT03325855
Recruiting
A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness
Gender:
All
Ages:
All
Trial Updated:
01/29/2024
Locations: MedStar Georgetown University Hospital, Georgetown, District of Columbia
Conditions: Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
Register for Updates
Collecting and Storing Tissue From Young Patients With Cancer
NCT00898755
Recruiting
This laboratory study is collecting and storing tissue, blood, and bone marrow samples from young patients with cancer. Collecting and storing samples of tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
Gender:
All
Ages:
21 years and below
Trial Updated:
01/29/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Acute Lymphoblastic Leukemia, Rhabdomyosarcoma, Acute Myeloid Leukemia, Central Nervous System Neoplasm, Ewing Sarcoma, Germ Cell Tumor, Leukemia, Lymphoma, Malignant Neoplasm, Neuroblastoma, Osteosarcoma, Retinoblastoma, Rhabdoid Tumor, Soft Tissue Sarcoma
Register for Updates
Augmented Reality For MRI-Guided Interventions
NCT06224933
Recruiting
The purpose of this study is to determine feasibility and safety of using an augmented reality system in patients undergoing MRI-Guided needle procedures.
Gender:
All
Ages:
Between 3 years and 21 years
Trial Updated:
01/24/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Infections, Pain, Diagnosis, Image Guided Needle Biopsy
Register for Updates
Human Epilepsy Project 3
NCT05374928
Recruiting
By carrying a careful, large-scale and ambitious prospective study of a cohort of participants with generalized epilepsy, the study team hopes to clarify the likelihood of response and remission in this type of epilepsy, and try to explore the underlying biological drivers of treatment response, including novel realms of exploration such as impact of the microbiome, and genetics. The identification of biomarkers that predict the likelihood of disease response would allow epilepsy patients to mak... Read More
Gender:
All
Ages:
13 years and above
Trial Updated:
01/24/2024
Locations: Georgetown University, Washington, District of Columbia
Conditions: Idiopathic Generalized Epilepsy
Register for Updates
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
NCT05338697
Recruiting
VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Stroke, Stroke, Acute, Stroke, Ischemic, Stroke Hemorrhagic
Register for Updates
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
NCT04203316
Recruiting
This trial studies the side effects of enasidenib and to see how well it works in treating patients with acute myeloid leukemia that has come back after treatment (relapsed) or has been difficult to treat with chemotherapy (refractory). Patients must also have a specific genetic change, also called a mutation, in a protein called IDH2. Enasidenib may stop the growth of cancer cells by blocking the mutated IDH2 protein, which is needed for cell growth.
Gender:
All
Ages:
Between 24 months and 21 years
Trial Updated:
01/19/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Register for Updates